1. Brunda MJ, Bellantoni D, Sulich V. In vivo anti-tumor activity of combinations of interferon a and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells. Int. J Cancer 1987; 40: 365–71.
2. Ciolli V, Gabriele L, Sestili P, et al. Host antitumor mechanism in the combined IL-1/IL-2 therapy in mice injected with highly metastatic Friend leukemia cells. Effects on rstablished metastases. J Exp Med 1991; 173: 313–22.
3. Iligo M, Sakurai M, Tamura T, Saijo N, Hoshi A. In vivo antitumor activity of multiple injections of recombinant interleukin-2, alone and in combination with three different types of recombinant interferon, on various syngenic murine tumors. Cancer Res 1988; 48: 260–4.
4. McIntosh JK, Mulè JJ, Krosnick JA. Rosenberg SA. Combination cytokine immunotherapy with tumor necrosis factor a, interleukin 2, and a-interferon and its synergistic antitumor effects in mice. Cancer Res 1989; 49: 1408–14.
5. Thurman GB, Seals C, Low TLK, and Goldstein AL. Restorative effects of thymosin polypeptides on purified protein derivative-dependent migration inhibition factor production by peripheral blood lymphocytes of adult thymectomized guinea pigs. J. Biol. Resp. Mod. 1984; 3: 160.